Laurent, A.; Abdel-Sayed, P.; Grognuz, A.; Scaletta, C.; Hirt-Burri, N.; Michetti, M.; de Buys Roessingh, A.S.; Raffoul, W.; Kronen, P.; Nuss, K.;
et al. Industrial Development of Standardized Fetal Progenitor Cell Therapy for Tendon Regenerative Medicine: Preliminary Safety in Xenogeneic Transplantation. Biomedicines 2021, 9, 380.
https://doi.org/10.3390/biomedicines9040380
AMA Style
Laurent A, Abdel-Sayed P, Grognuz A, Scaletta C, Hirt-Burri N, Michetti M, de Buys Roessingh AS, Raffoul W, Kronen P, Nuss K,
et al. Industrial Development of Standardized Fetal Progenitor Cell Therapy for Tendon Regenerative Medicine: Preliminary Safety in Xenogeneic Transplantation. Biomedicines. 2021; 9(4):380.
https://doi.org/10.3390/biomedicines9040380
Chicago/Turabian Style
Laurent, Alexis, Philippe Abdel-Sayed, Anthony Grognuz, Corinne Scaletta, Nathalie Hirt-Burri, Murielle Michetti, Anthony S. de Buys Roessingh, Wassim Raffoul, Peter Kronen, Katja Nuss,
and et al. 2021. "Industrial Development of Standardized Fetal Progenitor Cell Therapy for Tendon Regenerative Medicine: Preliminary Safety in Xenogeneic Transplantation" Biomedicines 9, no. 4: 380.
https://doi.org/10.3390/biomedicines9040380
APA Style
Laurent, A., Abdel-Sayed, P., Grognuz, A., Scaletta, C., Hirt-Burri, N., Michetti, M., de Buys Roessingh, A. S., Raffoul, W., Kronen, P., Nuss, K., von Rechenberg, B., Applegate, L. A., & Darwiche, S. E.
(2021). Industrial Development of Standardized Fetal Progenitor Cell Therapy for Tendon Regenerative Medicine: Preliminary Safety in Xenogeneic Transplantation. Biomedicines, 9(4), 380.
https://doi.org/10.3390/biomedicines9040380